Wim Vandenberghe

Partner

"We greatly appreciate Wim's vast knowledge and understanding of the medical device market. He is always flexible and responsive, and clients appreciate his calmness and expertise. He is an out-of-the-box thinker.”

Chambers Europe, Life Sciences: EU, client

“Wim was able to apply his detailed legal knowledge to the facts of our case and provide detailed and compelling guidance to support us."

Chambers Europe, Life Sciences: EU, client

"He stands out among peers for his rare combination of global legal insight, scientific literacy and pragmatic problem-solving."

Chambers Europe, Life Sciences: EU, client

Wim is an EU regulatory partner who focuses on the life sciences sector.

Wim helps pharmaceutical, medical device, cosmetics, and food companies navigate the regulatory process in Europe throughout the life cycle of their products – from planning and development to approval and marketing, and through to enforcement and ongoing compliance. His work has been recognised by The Legal 500 in its 2024 list of notable EU Regulatory: Pharma, Medical Devices, and Biotech practices.

This includes advising clients on a broad range of regulatory issues, such as regulatory pathways, product classification, marketing authorisations, CE marking, clinical trials, product, GxP/QMS requirements, internal compliance processes and procedures, advertising and promotion, HCP/HCO interactions (including fraud and abuse), market access, adverse event reporting and recalls, and digital health. He also assists clients with regulatory due diligence evaluations regarding the compliance status of acquisition targets in the life sciences sector, as well as post-acquisition integration.

He frequently works with Reed Smith’s U.S. FDA team to provide equivalent advice on EU regulations to the firm’s clients in international matters.

As a natural corollary of his regulatory practice, Wim has developed substantial experience in drafting and negotiating industry-specific agreements, including contract manufacturing, development and commercialisation, supply, quality and pharmacovigilance, distribution, and other related agreements (e.g., CTA, CRO, MSA, MTA, and API).

Wim has represented clients before EU and national regulatory agencies in investigations and enforcement matters. This work also includes carrying out internal audits, developing corporate compliance programmes, and assisting with supply chain and product liability claims.

In addition to his life sciences practice, Wim also advises more generally on EU market access matters in multiple industries, such as consumer products, industrial machinery, e-commerce, technology, and manufacturing, and he is a core member of the firm’s Retail and Consumer Goods Group. This work includes counselling on product standards (safety, health, and environment), regulatory compliance approvals (including CE marking, packaging, and labelling), cross-sectoral requirements (e.g., materials and waste management, sustainability, and carbon neutrality), and internal market issues. He advises on the legal, practical, and procedural aspects of EU law-making, engaging with EU institutions to anticipate, understand, and influence policy and the legislative and regulatory developments that impact clients’ businesses.

Wim has been quoted by The Wall Street Journal, The Economist, Politico, PaRR, Food Quality and Safety, New Europe Online, Bloomberg Businessweek, and Dow Jones Newswires.

Experience

Representative matters

Advised a consortium of medical device manufacturers on whether guidance issued by the European Commission – that would “up classify” software as a medical device as a higher risk medical device – was compatible with the EU Medical Device Regulation and general EU treaty law.

Advised a diabetes device manufacturer with overall compliance of its glucose monitoring system under medical device regulations, as well as other issues such as:

  • justified collection and use of patient data under medical device regulations versus data protection;
  • its collaboration agreement with a pharmaceutical company in terms of quality/safety/post market surveillance requirements as well as patient data sharing;
  • allegations of non-compliance with vigilance reporting duties;
  • misuse of its system by a third party for a nutrition coaching program; and
  • data sharing collaboration and informed consent requirements.
Reviewed marketing materials of a US medical device company following its obtaining of a CE mark to commercialise products in Europe.

Credentials

Education

  • University of Edinburgh, 2002, LL.M.
  • KU Leuven, 2001, LL.B.

Professional admissions & qualifications

  • Brussels

Court admissions

  • EU Court of Justice and General Court

Professional affiliations

  • Visiting lecturer, King’s College London (UK), 2012-2019

News

Blogs

Events